The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

A Lilly spokesperson said the company has no affiliation with Hims & Hers and noted that Zepbound may be cheaper ... pending post-launch probe Why Do Millennials Appear To Be Aging Slower?

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it ...

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper ...

13:04 EDT Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reports Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform ... including Eli Lilly’s in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at ...

Lilly said in a statement that Zepbound can be prescribed by any licensed healthcare professional, adding that it has no affiliation with Hims & Hers. (Reporting by Sneha S K and Puyaan Singh in ...